Shares of Bajaj Healthcare Ltd surged 4.30% to ₹616.40 on Tuesday, outperforming the weak market sentiment following the company’s Q3 FY25 earnings report. The pharmaceutical company posted a net profit of ₹11.7 crore, a significant turnaround from a ₹2.2 crore loss in Q3 FY24. Revenue grew 13.1% YoY to ₹122.8 crore, up from ₹108.6 crore in the same quarter last year, driven by steady demand for active pharmaceutical ingredients (APIs) and bulk drugs.
EBITDA stood at ₹21.7 crore, reflecting a 10.7% increase from ₹19.6 crore in the year-ago quarter. Meanwhile, EBITDA margin came in at 17.7%, slightly lower than 18.1% in the previous year.
The stock saw strong buying interest as investors reacted positively to the company’s improved profitability and revenue growth. The sharp recovery in earnings signals a strengthening financial position, positioning Bajaj Healthcare for further gains.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
